LingMaMDMS

Oncology • Denver, CO

Physician

Join to view full profile

Dr. Ma is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Ma's full profile

Already have an account?

Office
11750 W 2nd Pl
Ste 150
Denver, CO 80228
Phone+1 303-430-2700
Is this information wrong?

Education & Training

Baylor University Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2010
Indiana University School of MedicineResidency, Internal Medicine, 2005 - 2008
Shandong Medical UniversityClass of 1994

Certifications & Licensure

VA State Medical License 2024 - 2026
CO State Medical License 2010 - 2025
TX State Medical License 2009 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

5280 Top Doctor 2018, 2022

Publications & Presentations

PubMed

63 citations
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael A. Danso, Lazar Popovic, Timothy J. Pluard, Hyo S Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald A. Richa...> ;The Lancet. Oncology. 2019 Nov 1
199 citations
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrat...
Amit M. Oza, Anna V. Tinker, Ana Oaknin, Ronnie Shapira-Frommer, Iain A. McNeish, Elizabeth M. Swisher, Isabelle Ray-Coquard, Katherine M. Bell-McGuinn, Robert L. Cole...> ;Gynecologic Oncology. 2017 Nov 1
807 citations
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;The Lancet. Oncology. 2017 Jan 1
55 citations
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).
Vicky Makker, Fernando O. Recio, Ling Ma, Ursula A. Matulonis, Jennifer O. Lauchle, Hema Parmar, Houston Gilbert, Joseph A. Ware, Rui Zhu, Shan Lu, Ling-Yuh Huw, Yulei...> ;Cancer. 2016 Nov 15
Join now to see all

Hospital Affiliations

SCL Health - Lutheran Medical CenterWheat Ridge, Colorado